AF company Cardima raises $4.5 million for Revelation:
This article was originally published in Clinica
Cardima, which has developed the linear ablation system, Revelation Tx, for the treatment of atrial fibrillation, has completed a $4.5m private placement. The Fremont, California-based company plans to submit a premarket approval application for its product to the FDA this quarter. Atrial fibrillation, which affects some two million Americans and 4.5 million people worldwide, is believed to represent a potential $6bn market that is underserved by existing methods, Cardima says.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Guidelines outline permitted practices and patient safeguards for both physicians and technology platforms.
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.